UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of October 2017

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant's name into English)

Australia

(Jurisdiction of incorporation or organization)

Silviu Itescu Chief Executive Officer and Executive Director Level 38 55 Collins Street Melbourne 3000 Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:		
Form 20-F ☑ Form 40-F □		
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):		
Yes □ No ☑		
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):		
Yes □ No ☑		

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On October 6, 2017, Mesoblast Limited filed with the Austra (Appendix 3B), which is attached hereto as <u>Exhibit 99.1</u> , and	alian Securities Exchange a new issue an list incorporated herein by reference.	f additional securities and agreement

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Charlie Harrison

Charlie Harrison
Company Secretary

Dated: October 10, 2017

Item

99.1 Appendix 3B of Mesoblast Ltd, dated October 6, 2017.

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

ABN 68 109 431 870

MESOBLAST LIMITED (Mesoblast)

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- +Class of +securities issued or to be issued
- Number of +securities issued or to be issued (if known) or maximum number which may be issued
- Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Ordinary shares (fully paid) and unquoted options to acquire ordinary shares

158,901 fully paid ordinary shares and 400,000 unquoted options to acquire ordinary shares.

158,901 fully paid ordinary shares as per the company's constitution. The full amount of shares are to be held in voluntary escrow until 6 October 2018.

300,000 unquoted options to acquire ordinary shares at a price per share of A\$2.23, vesting in three equal tranches on 28 June 2018, 28 June 2019 and 28 June 2020 respectively, and expiring 27 June 2024.

100,000 unquoted options to acquire ordinary shares at a price per share of A\$1.54, vesting in three equal tranches on 16 September 2018, 16 September 2019 and 16 September 2020 respectively, and expiring 15 September 2024.

+ See chapter 19 for defined terms.

Appendix 3B Page 1 04/03/2013

4	Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?	
	If the additional +securities do not rank equally, please state:	Shares issued on the exercise of the unquoted options will rank equally with quoted shares as from their date of issue.
	 the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, 	
	distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next	
	dividend, distribution or interest payment	
5	Issue price or consideration	For the ordinary shares, US\$240,000
		Each option was issued for no issue price.
6	Purpose of the issue	158,901 ordinary shares as consideration for services in connection with the license of
	(If \dot{l} issued as consideration for the acquisition of assets, clearly identify those assets)	intellectual property relating to cell targeting technology (ex vivo fucosylation) from a third party.
		400,000 unquoted options to acquire ordinary shares issued pursuant to the Company's
		Employee Share Option Plan.
C		
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections $6b-6h$ in relation to the +securities the subject of this Appendix $3B$, and comply with section $6i$	
6b	The date the security holder resolution under rule 7.1A was passed	Not applicable
6c	Number of +securities issued without security holder approval under rule 7.1	Not applicable
6d	Number of +securities issued with security holder approval under rule 7.1A	Not applicable
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Not applicable
6f	Number of +securities issued under an exception in rule 7.2	Not applicable
6g	To be a sitted the second and a select 7.10 and the second and the	Not applicable
og	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	ivot applicable
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on	Not applicable
	which valuation of consideration was released to ASX Market Announcements	

+ See chapter 19 for defined terms.

Appendix 3B Page 2 04/03/2013

5i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Not applicable		
7 3	+Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable) Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	Date Registered 06/10/2017 Total Date Registered Date Registered 06/10/2017 Total Total Total Date Registered 06/10/2017 Total Total Number 470,601,826 Number 22,443,577 (156,669 options have been cancelled since last Appendix 3B) Appendix 3B Date Registered Regi	Number of unquoted options to acquire shares issued 400,000 400,000 Number of fully paid ordinary shares issued 158,901 158,901 +Class Ordinary shares Unquoted options	
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Appendix 3B) All ordinary shares rank equally and participate in the right to dividends equally.		
Par	t 2 - Pro rata issue			
11	Is security holder approval required?	Not applicable		
12	Is the issue renounceable or non-renounceable?	Not applicable		
13	Ratio in which the +securities will be offered	Not applicable		
14	+Class of +securities to which the offer relates	Not applicable		
15	+Record date to determine entitlements	Not applicable		
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable		
17	Policy for deciding entitlements in relation to fractions	Not applicable		
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with.	Not applicable		
19	Cross reference: rule 7.7. Closing date for receipt of acceptances or renunciations	Not applicable		
20	Names of any underwriters	Not applicable		
21	Amount of any underwriting fee or commission	Not applicable		
See c	napter 19 for defined terms.			
Append	ix 3B Page 3		04/03/2013	

22	Names of any brokers to the issue	Not applicable		
23	Fee or commission payable to the broker to the issue	Not applicable		
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable		
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable		
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable		
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable		
28	Date rights trading will begin (if applicable)	Not applicable		
29	Date rights trading will end (if applicable)	Not applicable		
30	How do security holders sell their entitlements $in\ full$ through a broker?	Not applicable		
31	How do security holders sell $part$ of their entitlements through a broker and accept for the balance?	Not applicable		
32	How do security holders dispose of their entitlements (except by sale through a broker)?	Not applicable		
33	+Issue date	Not applicable		
	3 - Quotation of securities d only complete this section if you are applying for quotation of securities Type of +securities			
51	(tick one)			
(a)	+Securities described in Part 1			
(b)	All other +securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully	paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
+ See ch	+ See chapter 19 for defined terms.			
Appendi	ix 3B Page 4	04/03/2013		

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to	Tick to indicate you are providing the information or documents			
35	indicate you are providing the information or documents If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders			
36	If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over			
37		A copy of any trust deed for the additional +securities		
Entit	ies that l	nave ticked box 34(b)		
38	Number of	+securities for which +quotation is sought	Not applicable	
39	+Class of +	securities for which quotation is sought	Not applicable	
40		curities rank equally in all respects from the +issue date with an ass of quoted +securities?	equally in all respects from the +issue date with an Not applicable +securities?	
	the date frthe extenttrust, distrthe extent	onal +securities do not rank equally, please state: rom which they do at to which they participate for the next dividend, (in the case of a ribution) or interest payment to which they do not rank equally, other than in relation to the next distribution or interest payment		
41	Reason for	request for quotation now	Not applicable	
	Example: In the	case of restricted securities, end of restriction period		
	(if issued u +security)	apon conversion of another +security, clearly identify that other		
			Number	+Class
42	Number and in clause 38	d +class of all +securities quoted on ASX (including the +securities b)	Not applicable	Not applicable
+ See cl	hapter 19 for d	efined terms.		

04/03/2013 Appendix 3B Page 5

Quotation agreement

- 1 +Quotation of our additional -securities is in ASX's absolute discretion. ASX may quote the -securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations
 Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that noone has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities
 be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 6 October 2017 Company secretary

Print name: Charlie Harrison

== == == ==

+ See chapter 19 for defined terms.

Appendix 3B Page 6 04/03/2013